CDC is updating webpages with the term "mpox" to reduce stigma and other issues associated with prior terminology. This change is aligned with the recent World Health Organization decision.

Preliminary JYNNEOS Vaccine Effectiveness Estimates Against Medically Attended Mpox Disease in the U.S., August 15, 2022 – October 29, 2022

JYNNEOS vaccine is effective at reducing the risk of mpox disease, with two doses providing the best protection, regardless of how the vaccine was administered.

VE of JYNNEOS against medically attended mpox disease

These unpublished data are from a matched case control study where cases are patients with an mpox diagnosis or positive laboratory result and controls are patients with an incident HIV diagnosis or HIV pre-exposure prophylaxis prescription. Data are subject to change.

Notes: This study was done in collaboration with Epic Research using data from Cosmos.